✦ LIBER ✦

Biological properties of the antagonist SRI 63–441 in the PAF and endotoxin models of hypotension in the rat and dog

✍ Scribed by Dean A. Handley; Ronald G. Van Valen; John C. Tomesch; Mary Kay Melden; James M. Jaffe; Frances H. Ballard; Robert N. Saunders

Publisher: Elsevier Science
Year: 1987
Tongue: English
Weight: 573 KB
Volume: 13
Category: Article
ISSN: 0162-3109
DOI: 10.1016/0162-3109(87)90049-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Inhibition and reversal of endotoxin-, a

Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist

✍ Dean A. Handley; Ronald G. Van Valen; Mary K. Melden; Stefan Flury; Mark L. Lee; 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 463 KB

Vascular responses of platelet-activatin

Vascular responses of platelet-activating factor in the Cebus apella primate and inhibitory profiles of antagonists SRI 63-072 and SRI 63-119

✍ Dean A. Handley; Ronald G. Van Valen; Robert N. Saunders 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 758 KB

Release of eicosanoids in rat peritonial

Release of eicosanoids in rat peritonial cavity during the Arthus reaction. Effect of the PAF-antagonist BN-52021 and indomethacin

✍ S. Jancar; P. Braquet; P. Sirois 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 304 KB

Pharmacokinetics of SB-247083, a potent

Pharmacokinetics of SB-247083, a potent and selective endothelinA receptor antagonist, in the rat, dog, and monkey

✍ Keith W. Ward; Leonard M. Azzarano; Jayme A. Morgan; Michael J. Gould; Cherng-Yi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

The pharmacokinetics and metabolism of C

The pharmacokinetics and metabolism of CP-191,166, an angiotensin II receptor antagonist, in rats and dogs

✍ Mary C. Allen; Mark R. Nocerini; Wesley W. Day 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

166 is an orally active, non-peptide angiotensin II (AII) receptor antagonist developed for the treatment of hypertension and congestive heart failure (CHF). In this study, the intravenous (iv) and oral (po) single dose pharmacokinetics (PK), oral multiple dose PK and P450-mediated metabolism of 16

The pharmacokinetics and metabolism of D

The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs

✍ Y. N. Wong; K. A. Holm; D. L. Burcham; S.-M. Huang; C. Y. Quon 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB 👁 1 views

DuP 532, 2-propy1-4-pentafluoroethyl-l-[ [2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylJ imidazole-5-carboxylic acid, is an orally active, non-peptide angiotensin I1 (AII) receptor antagonist. DuP 532 is more potent and longer acting than losartan, another A11 receptor antagonist currently undergoing ph